Loading clinical trials...
Loading clinical trials...
To investigate the efficacy and safety of RS-79070 when used as induction therapy in patients with newly diagnosed peripheral retinitis. To assess the effects of induction and maintenance level dosing of RS-79070 on CMV viral load, estimated by plasma CMV PCR. To assess the pharmacokinetics of ganciclovir following administration of RS-79070 in the target population.
Age
14 - No limit years
Sex
ALL
Healthy Volunteers
No
Univ of California / Irvine
Irvine, California, United States
Univ of California / San Diego / Dept of Pediatrics
La Jolla, California, United States
Univ of California / San Diego Treatment Ctr
San Diego, California, United States
Davies Med Ctr / Institute for HIV Research
San Francisco, California, United States
Kaiser Permanente Med Ctr
San Francisco, California, United States
QUEST Clinical Research
San Francisco, California, United States
Dr Alan Palestine
Washington D.C., District of Columbia, United States
Univ of Miami School of Medicine
Miami, Florida, United States
Emory Eye Clinic
Atlanta, Georgia, United States
New England Med Ctr
Boston, Massachusetts, United States
Start Date
January 1, 1997
Primary Completion Date
December 1, 2002
Completion Date
December 1, 2002
Last Updated
May 17, 2017
Valganciclovir
DRUG
Ganciclovir
DRUG
Lead Sponsor
Hoffmann-La Roche
NCT06694805
NCT04142047
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT07428330